China urges firms to avoid Nvidia H20 chips in sensitive work – Bloomberg
In a year marked by significant volatility, US Physical Therapy Inc (NYSE:USPH) stock has recorded a new 52-week low, dipping to $76.14. According to InvestingPro data, the stock’s RSI suggests oversold territory, while the company maintains a "GOOD" overall financial health rating. This latest price level reflects a stark contrast to the stock’s performance over the past year, with USPH experiencing a substantial 1-year change decline of -28.48%. Investors are closely monitoring the stock as it navigates through a challenging economic landscape, which has seen many companies in the healthcare sector face similar downward pressures. The 52-week low serves as a critical indicator for market watchers and shareholders, who are considering the company’s future prospects and potential for recovery. Notably, analysts maintain a positive outlook with price targets ranging from $98 to $120, suggesting potential upside. For deeper insights and access to comprehensive analysis, including 10+ additional ProTips and detailed valuation metrics, visit InvestingPro.
In other recent news, U.S. Physical Therapy reported its fourth-quarter 2024 earnings, revealing an earnings per share (EPS) of $0.52, which fell short of the expected $0.69. Despite this, the company exceeded revenue forecasts, achieving $180.45 million, demonstrating strong sales performance. The company has been expanding its market presence by adding approximately 70 clinics and entering new states, such as Wyoming and Pennsylvania. However, anticipated Medicare rate cuts pose future financial challenges, potentially impacting profitability. On the analyst front, there was no specific mention of upgrades or downgrades, but firms like Jefferies and William Blair participated in the earnings call, showing continued interest in the company’s performance. U.S. Physical Therapy’s strategic focus includes increasing reimbursement rates and expanding home-based therapy services. The company expects its EBITDA for 2025 to be between $88 million and $93 million, with potential impacts from Medicare rate reductions. The company is also piloting AI-driven note systems and virtual staffing to improve operational efficiency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.